Recent advances in the management of juvenile systemic sclerosis

Francesco Zulian1, Marta Balzarin1, Carolina Birolo1

  • 1a Pediatric Rheumatology Unit, Department for Woman and Child Health , University of Padua , Padua , Italy.

Insights

Juvenile Systemic Sclerosis (JSSc) is a severe pediatric condition requiring early diagnosis and management. Recent advances in classification and assessment tools like J4S aid clinical practice and research, though effective treatments remain limited.

Area of Science:

  • Pediatric Rheumatology
  • Connective Tissue Diseases

Background:

  • Juvenile Systemic Sclerosis (JSSc) is a severe multi-systemic connective tissue disease in children.
  • High morbidity and mortality rates necessitate early diagnosis, assessment, and treatment.

Purpose of the Study:

  • To review recent advances in the classification and general management of JSSc.
  • To highlight new assessment tools and their impact on clinical practice and research.

Main Methods:

  • Literature search on JSSc classification and management.
  • Incorporation of authors' clinical experience.

Main Results:

  • New classification criteria and assessment tools, such as the J4S score, are proposed.
  • Novel techniques for internal organ assessment are discussed.
  • Current treatments show limited efficacy in preventing complications but may arrest disease progression.

Conclusions:

  • Advances in classification and assessment tools are crucial for managing JSSc.
  • Effective treatments for JSSc remain a significant challenge, with adult-based therapies showing some promise.
Abstract

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
602
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
294
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
451
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
415
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
296
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558